Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe

Abstract

Valeria Magarotto,1 Julien Thevenon,2 Kate Morgan,3 Silene ten Seldam,3 Wafae Iraqi,4 Xavier Guillaume,5 Marjorie Leclerc,5 Claire Graziani-Taugeron,5 Bleuenn Rault,5 Dahbia Horchi5 1MD, Janssen-Cilag, Cologno Monzese, MI, Italy; 2Medical Affairs, Janssen Pharmaceuticals, Issy-les-Moulineaux, France; 3Myeloma Patients Europe, Brussels, Belgium; 4Patient Engagement, Janssen Pharmaceuticals, Issy-les-Moulineaux, France; 5RWE Data & Analytics, Oracle Life Sciences, Paris, FranceCorrespondence: Xavier Guillaume; Claire Graziani-Taugeron, Oracle France, 198 Avenue de France, Paris, 75013, France, Email [email protected]; [email protected]: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab.Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study.Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients’ treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p< 0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p< 0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p< 0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey.Conclusion: In line with results from other studies, the SC form of daratumumab had less impact on patients’ emotional burden than the IV form.Keywords: multiple myeloma, daratumumab, mode of administration, patients’ emotional burden, mixed method

Keywords

• multiple myeloma
• daratumumab
• mode of administration
• patients’ emotional burden
• mixed method